AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, ...

The trial judged the tolerability, safety and efficacy of atogepant, at 60 mg once daily, compared to the highest-tolerated ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

Now is a great time for income and value investors, especially in energy and pharma, with dividends and upside potential.

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

DelveInsight's “Vitiligo Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.